Atlas Trials

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Clinical trial NCT03433781 · COMPLETED

Trial details

NCT number
NCT03433781
Sponsor
NYU Langone Health
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2018-05-01
Primary completion
2022-11-06
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.